Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

Tamburini, J; Elie, C; Park, S; Beyne-Rauzy, O; Gardembas, M; Berthou, C; Mahe, B; Sanhes, L; Stamatoullas, A; Vey, N; Aouba, A; Slama, B; Quesnel, B; Vekhoff, A; Sotto, J J; Vassilief, D; Al-Nawakil, C; Fenaux, P; Dreyfus, F; Bouscary, D

Tamburini, J; Elie, C; Park, S; Beyne-Rauzy, O; Gardembas, M; Berthou, C; Mahe, B; Sanhes, L; Stamatoullas, A; Vey, N; Aouba, A; Slama, B; Quesnel, B; Vekhoff, A; Sotto, J J; Vassilief, D; Al-Nawakil, C; Fenaux, P; Dreyfus, F; Bouscary, D.

Affiliation

Tamburini J; Department of haematology, Hôpital Cochin, France. tamburini@cochin.inserm.fr

Leuk Res ; 33(4): 547-50, 2009 Apr.

Article in En | MEDLINE | ID: mdl-18640718

Subject(s)

Angiogenesis Inhibitors/administration & dosage; Angiogenesis Inhibitors/adverse effects; Myelodysplastic Syndromes/drug therapy; Thalidomide/administration & dosage; Thalidomide/adverse effects; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Myelodysplastic Syndromes / Angiogenesis Inhibitors Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2009 Document type: Article

Fulltext

XML

PubMed Links

Search on Google